U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT06841068) titled 'Intrathecal Amniotic Fluid Stem Cells for Progressive Multiple Sclerosis' on Feb. 16.
Brief Summary: In this clinical trial, researchers are exploring a novel approach to delivering therapy directly into the spinal fluid, which surrounds and nourishes the brain and spinal cord. The study focuses on patients with progressive multiple sclerosis (MS), a form of the disease that leads to worsening disability without the typical relapses seen in other MS subtypes.
This investigational therapy involves the use of stem cells derived from amniotic fluid-the protective liquid surrounding a developing baby in the womb. To the best of the res...